118th congress, Congress

Michigan [US], August 21 : Men appeared to experience greater rates of severe sickness and mortality at the beginning of the COVID pandemic, which led researchers to hypothesise a connection between androgen receptors—which bind to hormones like testosterone—and SARS-CoV-2 virus infection.This discovery prompted researchers at Michigan Medicine to investigate proxalutamide, a medicine being developed to treat prostate cancer that prevents the action of an androgen receptor-controlled enzyme called TMPRSS2 (transmembrane protease, serine 2), as a potential treatment for COVID.“We were already studying TMPRSS2 as part of the key gene driver of over 50 percent of prostate cancer, so it made sense to look at it as TMPRSS2 is an important host factor for SARS-CoV2 to enter cells in the lung,” said Arul Chinnaiyan, M.D., Ph.D., director of the Michigan Center for Translational Pathology and the S.P. Hicks Endowed Professor of Pathology.Chinnaiyan, co-principal investigator Jonathan Sexton, Ph.D., assistant professor of Internal Medicine at the University of Michigan Medical School and Assistant professor of medicinal chemistry in the College of Pharmacy and their team recently published their study in PNAS.The team added proxalutamide to cells infected with SARS-Co-V2 to monitor its ability to block viral entry.The compound works by binding to androgen receptors, inhibiting levels of TMPRSS2 and ACE2, and blocking infection.What’s more, proxalutamide worked better than other prostate cancer drugs against multiple variants of SARS-CoV2 due to its ability to break down the androgen receptor.Additionally, proxalutamide, when combined with FDA-approved COVID drug remdesivir, blocked infection by 100%.“This discovery underscores the utility of testing existing drugs for new applications that can be rapidly evaluated in humans to shorten the timeline from discovery to clinical evaluation," said Sexton, who is also director of the U-M Center for Drug Repurposing.Buoyed by their in vitro results, the team looked to see whether the compound could stop the so-called cytokine storm, or severe inflammatory response, caused by SARS-CoV-2 infection.Using a mouse model, they demonstrated that the drug reduced inflammation and cell death in the lungs of mice and reduced mortality.Said Chinnaiyan, “The thought is proxalutamide could work as a combined therapy with remdesivir, hitting the virus from multiple angles, much as combination therapy works so well for HIV infection.”The drug is currently in phase 3 clinical trials for prostate cancer and early clinical trials for COVID.Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

118Th CongressFOLLOW

118th congress, Latest News

Noida, Aug 21 Members of the Bharatiya Kisan Parishad clashed with the police in Noida on Monday. The ... ...

Hyderabad, Aug 21 The Bharath Rashtra Samithi (BRS), which announced 115 candidates on Monday for the upcoming Assembly ... ...

Lokmat News Network Chhatrapati Sambhajinagar: After enjoying relief for a few months, the citizens once again grieved and complained ... ...

Chennai, Aug 21 India’s 18-year-old Grandmaster (GM) R. Praggnanandhaa (ELO 2,707) took lead in the tie-break of FIDE ... ...

Bhopal, Aug 21 Newly established Mauganj District Collector Ajay Srivastava has said that inadequate facilities at the premises ... ...

New Delhi, Aug 21 To bring in more flexibility in the squad ahead of the Men’s ODI World ... ...

Bengaluru (Karnataka)[India], August 21 : The Mysuru Warriors produced a fine chase to hand the Hubli Tigers their first ... ...

Michigan [US], August 21 : Men appeared to experience greater rates of severe sickness and mortality at the beginning of ... ...